결핵 치료제 시장 : 결핵 유형, 투여 경로, 약제 클래스별, 연령층, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Tuberculosis Drugs Market is projected to grow by USD 3.14 billion at a CAGR of 5.03% by 2032.

Tuberculosis drugs remain central to global infectious disease control as TB continues to rank among the world's deadliest communicable diseases. The World Health Organization (WHO) reported that an estimated 10.8 million people developed TB in 2023 and 1.25 million people died from the disease, underscoring sustained need for first-line tuberculosis treatment, drug-resistant TB regimens, pediatric TB formulations, and adherence-enabling delivery models.

Commercial priorities are being shaped by two concurrent realities: most drug-susceptible TB is still treated with established rifamycin-, isoniazid-, pyrazinamide-, and ethambutol-based regimens, while multidrug-resistant TB and rifampicin-resistant TB require newer all-oral options such as bedaquiline-, pretomanid-, linezolid-, and moxifloxacin-containing combinations. For pharmaceutical manufacturers, global health procurers, and public-sector buyers, opportunity is tied less to premium pricing and more to reliable supply, differentiated formulations, quality assurance, pharmacovigilance, and alignment with WHO tuberculosis treatment guidelines.

Market Shifts Reshaping TB Therapeutics

The tuberculosis drugs landscape is shifting from long, injectable-heavy treatment pathways toward shorter, all-oral, patient-centered regimens. WHO recommendations for six-month BPaLM and BPaL-based regimens for eligible multidrug-resistant or rifampicin-resistant TB patients have materially changed procurement expectations by increasing the strategic relevance of bedaquiline, pretomanid, linezolid, and fluoroquinolone supply continuity.

At the same time, TB prevention and latent tuberculosis infection treatment are gaining policy attention in low-incidence markets and among high-risk populations. Shorter preventive therapy regimens using rifapentine and isoniazid are improving completion rates versus longer isoniazid monotherapy, creating demand for formulations and distribution models that fit community-based care, migrant health programs, HIV services, occupational screening initiatives, and contact-tracing programs.

AI Impact on TB Drug Discovery and Care

Artificial intelligence is beginning to influence the tuberculosis drugs ecosystem by improving screening efficiency, accelerating target identification, and strengthening pharmacovigilance. WHO has recognized computer-aided detection for chest radiography as a screening tool in defined settings, which can expand timely identification of people who require confirmatory testing and appropriate TB therapy initiation when linked to reliable diagnostic and medicine access pathways.

For manufacturers and research organizations, AI-enabled molecular modeling, literature mining, resistance prediction, safety-signal detection, and trial-site optimization can reduce friction in TB drug development. However, measurable commercial and clinical impact depends on validation, regulatory acceptance, representative datasets, and integration with laboratory confirmation, because AI cannot substitute for microbiological diagnosis, drug-susceptibility testing, or evidence from controlled clinical trials.

Regional Demand Patterns for TB Drugs

Asia-Pacific is the most consequential demand center for tuberculosis drugs because WHO identifies India, Indonesia, China, the Philippines, Pakistan, Bangladesh, and other regional markets among the major contributors to global TB incidence. India alone accounts for roughly one-quarter of the global TB burden, making public procurement, domestic manufacturing, fixed-dose combinations, and shorter treatment adoption central to regional access. In parallel, high-burden Asia-Pacific settings are prioritizing diagnostic scale-up, private-sector engagement, pediatric TB care, and drug-resistant TB treatment capacity.

North America and Europe have lower TB incidence but remain important for latent tuberculosis infection management, migrant health programs, specialty drug-resistant TB care, strict regulatory oversight, and pharmacovigilance requirements. Latin America, led by Brazil, Peru, and Mexico, shows sustained need for public-sector treatment supply, adherence programs, and urban TB control. The Middle East's tuberculosis drug demand is influenced by expatriate and migrant worker screening, cross-border mobility, and centralized hospital procurement, while Africa remains a high-priority region because TB-HIV coinfection, diagnostic gaps, financing constraints, and medicine availability continue to shape demand for affordable first-line drugs and scalable drug-resistant TB regimens.

Strategic Group-Level TB Drug Signals

ASEAN is strategically important for tuberculosis drug suppliers because Indonesia, the Philippines, Vietnam, Myanmar, and Thailand combine high disease burden with expanding national TB programs and donor-supported procurement. The region's market dynamics favor quality-assured generics, pediatric formulations, fixed-dose combinations, shorter regimens, and decentralized care models that support treatment completion across urban, rural, and island geographies.

The GCC is a lower-incidence but operationally important group where expatriate health screening, hospital procurement, and antimicrobial stewardship influence demand for tuberculosis therapeutics. The European Union and G7 markets emphasize regulatory compliance, latent TB management, surveillance-led treatment, and specialty care for drug-resistant disease, while NATO countries also prioritize infectious disease surveillance, medical readiness, and resilient medicine supply chains. BRICS is the most consequential group for volume and policy influence because India, China, Russia, Brazil, and South Africa collectively include major TB and drug-resistant TB burdens, significant domestic manufacturing capacity, and large public-sector purchasing systems.

Country-Level TB Drug Opportunities

In the United States, the CDC reported 9,633 TB cases in 2023, reinforcing demand for targeted active TB treatment, latent tuberculosis infection therapy, and rapid access to drug-resistant TB expertise. Canada and Australia maintain low-incidence profiles but require steady supply for foreign-born populations, Indigenous communities, and specialized public health programs. Mexico and Brazil remain key Latin American markets because urban transmission, social determinants, and public-sector treatment programs sustain demand for quality-assured first-line medicines and adherence support.

Across Europe, the United Kingdom, Germany, France, Italy, and Spain focus on surveillance-led treatment, migrant screening, latent TB strategies, and guideline-compliant medicine access, while Russia remains particularly significant for multidrug-resistant TB and rifampicin-resistant TB management. China and India are decisive volume markets, with India driving the largest global treatment need and China emphasizing scale, surveillance, and domestic production. Japan and South Korea are mature healthcare markets where aging populations, low-to-moderate incidence, hospital-based care, and strong regulatory expectations shape demand for reliable TB therapeutics.

Recommendations for TB Drug Leaders

Industry leaders should prioritize supply resilience for rifampicin, isoniazid, pyrazinamide, ethambutol, rifapentine, bedaquiline, pretomanid, linezolid, and moxifloxacin, because stockouts can directly affect treatment completion and resistance prevention. Companies should align portfolios with WHO guidance, national essential medicines lists, pharmacovigilance expectations, and Global Drug Facility quality requirements to strengthen eligibility for public procurement.

Manufacturers can improve competitiveness by investing in heat-stable formulations, pediatric dispersible products, fixed-dose combinations, shorter-regimen packaging, robust quality systems, and country-specific access partnerships. R&D leaders should focus on safer sterilizing regimens, resistance-sparing combinations, long-acting or adherence-supporting approaches, and biomarkers that shorten trials while maintaining rigorous evidence standards.

Evidence-Based Research Methodology

This executive summary is built from verified public-health and regulatory evidence, including WHO Global TB Programme data, national TB surveillance agencies, peer-reviewed clinical trial evidence, FDA and EMA product information, treatment guideline updates, and procurement-oriented sources such as the Stop TB Partnership Global Drug Facility.

The methodology applies triangulation across epidemiology, treatment algorithms, country burden, procurement practices, regulatory pathways, resistance patterns, and pipeline signals. Insights are validated through cross-comparison of incidence trends, drug-resistance burden, policy adoption, therapy availability, and guideline evolution to ensure that conclusions reflect documented market realities rather than speculative estimates.

Strategic Conclusion

The tuberculosis drugs market is defined by persistent disease burden, rising attention to drug-resistant TB, and the transition toward shorter, all-oral, patient-centered regimens. Demand remains highest where TB incidence is concentrated, but high-income markets also play an important role in latent tuberculosis infection treatment, innovation adoption, pharmacovigilance, and regulatory standard-setting.

Organizations that combine reliable supply, WHO-aligned portfolios, evidence-based innovation, quality-assured manufacturing, and access-focused partnerships will be best positioned to serve public health needs while building durable relevance in tuberculosis therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tuberculosis Drugs Market, by Tuberculosis Type

• 7.1. Active Tuberculosis
  • 7.1.1. Drug-Susceptible Tuberculosis
    • 7.1.1.1. Pulmonary Tuberculosis
    • 7.1.1.2. Extrapulmonary Tuberculosis
  • 7.1.2. Drug-Resistant Tuberculosis
    • 7.1.2.1. Multidrug-Resistant Tuberculosis
    • 7.1.2.2. Extensively Drug-Resistant Tuberculosis
• 7.2. Latent Tuberculosis Infection

8. Tuberculosis Drugs Market, by Route Of Administration

• 8.1. Injectable
• 8.2. Oral

9. Tuberculosis Drugs Market, by Drug Class

• 9.1. Rifamycins
• 9.2. Fluoroquinolones
• 9.3. Aminoglycosides
• 9.4. Oxazolidinones
• 9.5. Nitroimidazoles

10. Tuberculosis Drugs Market, by Age Group

• 10.1. Pediatrics
• 10.2. Adults

11. Tuberculosis Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Tuberculosis Drugs Market, by End User

• 12.1. Hospitals
• 12.2. Specialty Clinics
• 12.3. Tuberculosis Treatment Centers
• 12.4. Homecare Settings

13. Tuberculosis Drugs Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Tuberculosis Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Tuberculosis Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Johnson & Johnson Services, Inc.
• 17.2. Hikma Pharmaceuticals PLC
• 17.3. Sanofi S.A.
• 17.4. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• 17.5. Cipla Limited
• 17.6. GlaxoSmithKline PLC
• 17.7. Eli Lilly and Company
• 17.8. Viatris Inc.
• 17.9. FarmaVision Healthcare
• 17.10. SiNi Pharma Pvt Ltd
• 17.11. AstraZeneca PLC
• 17.12. Cadila Pharmaceuticals Limited
• 17.13. Fresenius SE & Co. KGaA
• 17.14. Lupin Limited
• 17.15. Macleods Pharmaceuticals Ltd.
• 17.16. Merck & Co., Inc.
• 17.17. Otsuka Pharmaceutical Co., Ltd.
• 17.18. Pfizer Inc.
• 17.19. Sandoz International GmbH
• 17.20. Sun Pharmaceutical Industries Ltd.
• 17.21. Teva Pharmaceutical Industries Ltd.